Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $37
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $37
Baird維持Castle Biosciences的跑贏大盤評級，將目標價上調至37美元
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $34 to $37.
Baird分析師Catherine Ramsey維持對castle biosciences (納斯達克:CSTL)的表現優異評級，並將價格目標從34美元上調至37美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。